Core Insights - Pro Pharmaceutical (000739.SZ) reported a revenue of 5.444 billion yuan for the first half of 2025, representing a year-on-year decrease of 15.31% [1] - The net profit attributable to shareholders was 563 million yuan, down 9.89% year-on-year [1] - The net profit excluding non-recurring gains and losses was 521 million yuan, a decrease of 13.59% year-on-year [1] - Basic earnings per share were 0.4861 yuan [1] - The company plans to distribute a cash dividend of 3.4835 yuan (including tax) for every 10 shares to all shareholders [1] Revenue Breakdown - The sales revenue from the raw material pharmaceutical intermediates business was 3.603 billion yuan, a year-on-year decline of 23.41% [1] - The gross profit from this segment was 493 million yuan, down 35.32% year-on-year [1] - The gross margin for this business was 13.70%, which is a decrease of 2.52 percentage points year-on-year [1]
普洛药业(000739.SZ)发布上半年业绩,归母净利润5.63亿元,下降9.89%